Earnings
NexgenRx Announces 2025 Year End Results with Continued Increasing Net Income, EBITDA And Revenue Growth
Steady Growth Masks High Payout Ratio and Micro-Cap Liquidity Risks
Executive Summary
- NexgenRx released its full-year 2025 financial results on March 31, 2026, reporting revenue of $14.93M, an 8.84% year-over-year increase.
- EBITDA reached $3.35M, up $1.01M from 2024, while net income climbed to $1.29M, representing a 59% YoY increase.
- The company ended the fiscal year with $4.78M in cash after distributing $1.30M in dividends to common and preferred shareholders.
- Management highlighted a 12% combined increase in administration and transaction revenue, emphasizing recurring revenue stability and a healthy sales pipeline for 2026.
- This follows the Q3 2025 release (November 2025), which showed stronger quarterly momentum with 13.43% revenue growth and $0.89M EBITDA, and a December 2025 dividend declaration of $0.005 per share.
Material Impact
- The FY2025 results confirm a steady, predictable growth trajectory but do not introduce unexpected catalysts or operational shifts.
- The full-year revenue growth of 8.84% trails the Q3 quarterly growth rate of 13.43%, indicating Q4 2025 growth decelerated.
- Cash improved from $2.54M at the end of Q3 to $4.78M at year-end, driven by seasonal collections and operational cash flow.
- The dividend payout of $1.30M nearly matches the full-year net income of $1.29M, leaving virtually zero retained earnings for reinvestment. This high payout ratio is a structural constraint for a company claiming to fund new product launches and pipeline expansion.
- Market reaction has been muted. The stock peaked at $0.43 in November 2025 following the Q3 beat and has since drifted into the $0.31-$0.36 range, suggesting the positive results were already priced in and investors are cautious about the payout-to-earnings dynamic.
NXG · Price
Company Overview
- NexgenRx operates in the healthcare technology and pharmacy services sector, generating revenue through administration, transaction processing, and recurring software/service models.
- The flagship offering centers on pharmacy management and administrative platforms that streamline transaction workflows for healthcare providers.
- The business model relies heavily on recurring revenue streams and a sales pipeline focused on expanding market presence and deploying new product solutions in 2026.
- No specific flagship project name or detailed product roadmap was disclosed in the provided releases.